Results 111 to 120 of about 1,239,019 (334)

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential [PDF]

, 2016
The apigenin-phospholipid phytosome (APLC) was developed to improve the aqueous solubility, dissolution, in vivo bioavailability, and antioxidant activity of apigenin.
Anand, Sridhar, Dave, Vivek S., Fegade, Harshal, Patin, Arun T., Pethe, Anil M., Telange, Darshan R.   +5 more
core   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Impact of population based indoor residual spraying with and without mass drug administration with dihydroartemisinin-piperaquine on malaria prevalence in a high transmission setting: a quasi-experimental controlled before-and-after trial in northeastern Uganda [PDF]

, 2023
Dorothy C. Echodu, Adoke Yeka, Thomas Eganyu, Wycliff Odude, Fred Bukenya, Benjamin Amoah, Humphrey Wanzira, Kathryn Colborn, Richard Elliott, Suzanne E. Powell, Maxwell Kilama, Ronald Mulebeke, Joaniter I. Nankabirwa, Emanuele Giorgi, Mellisa Roskosky, Osborn Omoding, Samuel Gonahasa, Jimmy Opigo   +17 more
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

A Study of Coverage and Compliance of Mass Drug Administration for Elimination of Lymphatic Filariasis in Rewa District Of Madhya Pradesh

National Journal of Community Medicine, 2014
Introduction: Lymphatic filariasis (LF), commonly known as elephantiasis is a global problem affecting more than 120 million people in 80 countries. It is one of the leading causes of long term permanent disability, accounting for more than 5 million ...
Amarnath Gupta, Pankaj Prasad, Sukhendra P Singh   +2 more
doaj  

Mass Drug Administration (MDA) for Schistosomiasis [PDF]

Journal of Infectious Diseases, 2014
Wei, Wang, Yousheng, Liang
openaire   +2 more sources

Interplay between RNA‐protein interactions and RNA structures in gene regulation

FEBS Open Bio, EarlyView.
Methodological advances in mapping transcriptome‐wide RNA‐protein interactions and RNA structures have started to uncover the potential of RNP conformations in gene regulation. Competing RNA–RNA, RNA‐protein and protein–protein interactions shape the compaction and function of RNPs throughout their lifetime and may provide novel therapeutic targets in ...
Jenni Rapakko, Mauro Scaravilli, Minna‐Liisa Änkö   +2 more
wiley   +1 more source

The feasibility and acceptability of mass drug administration for malaria in Cambodia: a mixed-methods study [PDF]

, 2018
Thomas J. Peto, Rupam Tripura, Nou Sanann, Bipin Adhikari, James J. Callery, Mark Droogleever, Chhouen Heng, Phaik Yeong Cheah, Chan Davoeung, Chea Nguon, Lorenz von Seidlein, Arjen M. Dondorp, Christopher Pell   +12 more
openalex   +1 more source